



EY Entrepreneur of the year-2013



FROST & SULLIVAN Best Practices-2013



Business today/YES bank Excellence Awards-2013



Date: 03.12.2019

To The Department of Corporate Services BSE Limited Phiroze Jeejeebhoy Towers Dalal Street Mumbai- 400001 Security Code: 540596	To National Stock Exchange of India Limited Exchange Plaza Bandra Kurla Complex Bandra (E) Mumbai-400051 Symbol: ERIS
---	---

Dear Sir/Madam,

Sub: Intimation of acquisition of trademark- Zomelis together with its associated trademarks

We hereby notify having acquired trademark 'Zomelis' and its associated trademarks from Novartis AG, based at Basel Switzerland for Indian pharmaceuticals market with effect from 10th December 2019. The other details connected to the transaction are as under:

1. The trademark has been used for marketing Vildagliptin formulations; an oral anti-diabetic drug that has been promoted in India for close to 10 years;
2. The trademark along with its applicable associate marks presently enjoy sales on a moving annual total (MAT) basis of Rs.63.96 Crores¹;
3. One of the Indian patents pertaining to Vildagliptin, namely Patent No. 212815 of the Patent holder, shall expire in the month of December 2019. The assignment of Zomelis trademark, which enjoys aforementioned patent exclusivity, is expected to provide a head-start to Eris vis-à-vis other branded generic players after the scheduled expiry of the aforementioned patent.
4. The consideration involved in this trademark acquisition is USD 13 Million.

Eris Lifesciences Limited

Milind Talegaonkar
Company Secretary & Compliance Officer

1. AIOCD Pharmasofttech AWACS Pvt. Ltd. October 2019 dataset

Registered & Corporate Office:

8th Floor, Commerce House - IV, Prahlad Nagar, Ahmedabad - 380 015, Gujarat, India

Phone: +91 - 79 - 30451111 / 30179400 - 03 • Fax: +91 - 79 - 30179404 / 30451001 • Email: eris@erislifesciences.com • Web Site: www.eris.co.in

CIN: L24232GJ2007PLC049867